Resverlogix Corp. (TSE:RVX)’s stock price was up 15% on Monday . The stock traded as high as C$1.15 and last traded at C$1.15, approximately 180,302 shares were traded during mid-day trading. An increase of 46% from the average daily volume of 123,209 shares. The stock had previously closed at C$1.00.
The company’s fifty day moving average is C$1.76 and its two-hundred day moving average is C$2.85. The stock has a market cap of $253.08 million and a price-to-earnings ratio of -2.01.
Resverlogix (TSE:RVX) last issued its earnings results on Monday, September 16th. The biotechnology company reported C($0.07) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of C($0.13) by C$0.06. Equities research analysts predict that Resverlogix Corp. will post -0.22 EPS for the current fiscal year.
In other Resverlogix news, Senior Officer Dr. Jan Ove Johansson sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of C$2.89, for a total value of C$28,877.64. Following the transaction, the insider now directly owns 117,360 shares in the company, valued at C$338,907.98.
Resverlogix Company Profile (TSE:RVX)
Resverlogix Corp., a development stage company, develops small molecule therapeutics for bromodomain and extra-terminal (BET) inhibitior in the United States and Canada. It is developing apabetalone (RVX-208), a small molecule selective BET bromodomain inhibitor that is in Phase III clinical trials for the treatment of patients with cardiovascular diseases, diabetes mellitus, chronic kidney diseases, renal diseases, peripheral artery diseases, orphan diseases, and neurodegenerative diseases.
See Also: Quiet Period Expirations Explained
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.